AUTHORS
Jinuo Wang, MD, Jiahe Li2, Jianmei Xu3, Gang Wang4, Junyu Zhang5, Lihong Shou6, Kaihong Xu7, Xianting Wang8, Hui Zeng9, Songdi Chen10, Xiaoyan Han11, Jingsong He, PhD12, Wenjun Wu, MD13, Hua Xue14, Zhen Cai, MD,PhD15
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 The Affiliated Hospital of Hebei University, Shijiazhuang, China
4 Quzhou People’s Hospital, the Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou, China
5 Lishui Central Hospital, Lishui, China
6 Huzhou Central Hospital, Huzhou, China
7 The First Affiliated Hospital of Ningbo University, Ningbo, China
8 Taizhou First People ' s Hospital , Huangyan Hospital of Wenzhou Medical University, Taizhou, China
9 The First Affiliated Hospital of Jiaxing, Jiaxing, China
10 The First People’s Hospital of Yuhang District, Hangzhou, Hangzhou, China
11 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14 The Affiliated Hospital of Hebei University, Shijiazhuang, China
15 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background: Patients aged 80 years or older with multiple myeloma (MM) are underrepresented in clinical trials, and treatment decisions are often based on chronologic age rather than disease biology, functional status, or treatment deliverability. We evaluated prognostic factors and developed a simple treatment-course risk score for this population.
Methods: We retrospectively analyzed 145 patients diagnosed with MM at age 80 years or older between July 2013 and April 2025 across nine Chinese tertiary hospitals. OS and PFS were estimated by Kaplan-Meier methods, and prognostic factors were evaluated using Cox models. Treatment completion was defined as at least four cycles or four months of therapy. A 4-month landmark analysis addressed guarantee-time bias. A score assigning one point each for ISS III, ECOG at least 3, and incomplete treatment was assessed in the derivation cohort and an external cohort.
Results: Median age was 83 years (range, 80-92); 94 patients (64.8%) were male and 130 (89.7%) had ECOG at least 2. ISS was evaluable in 131 patients, including 91 (69.5%) with stage III disease. High-risk cytogenetics was present in 15 of 89 evaluable patients (16.9%). Among 136 patients with first-line treatment data, 91 (66.9%) received a proteasome-inhibitor-based regimen and 18 (13.2%) received a daratumumab-based regimen. Sixty-two patients (42.8%) completed at least four cycles/months. Completion rates were 45.4% at age 80-84 and 35.1% at age at least 85 years (P=0.337). Completion groups were similar for baseline clinical features, except serum calcium (median 2.22 vs 2.16 mmol/L; P=0.019); regimen distribution did not differ significantly (P=0.164). No prespecified binary predictor was associated with completion. Survival data were available for 137 patients (94.5%). Median follow-up was 35.0 months, median PFS 29.0 months, and median OS 39.0 months. Age 80-84 versus at least 85 years did not distinguish PFS (P=1.000) or OS (P=0.206). ECOG category distinguished PFS (P=0.011) and OS (P<0.001), and ISS I-II versus III distinguished both endpoints (both P<0.001). R-ISS I-II versus III was not significant for PFS (P=0.468) or OS (P=0.055). Among OS-evaluable patients, the 30-day and 90-day mortality rates were 5/137 (3.6%) and 12/137 (8.8%),respectively. Unadjusted treatment-completion comparisons were not significant for PFS (P=0.581) or OS (P=0.105). The 4-month landmark analysis included 112 patients and was also null for PFS (P=0.315) and OS (P=0.960). In the primary OS model (N/events=123/56), male sex (HR 2.039, 95% CI 1.106-3.761; P=0.023), incomplete treatment (HR 2.046, 95% CI 1.178-3.553; P=0.011), ECOG category (overall P=0.002), and ISS stage (overall P=0.002) were retained; age group was not significant (P=0.403). In a marker-adjusted model, LDH at least 250 U/L (HR 2.969, 95% CI 1.283-6.869; P=0.011) and β-2 microglobulin at least 5.5 mg/L (HR 4.230, 95% CI 1.526-11.729; P=0.006) were associated with OS. In the primary PFS model (N/events=123/67), male sex (HR 2.489, 95% CI 1.394-4.444; P=0.002), ECOG category (overall P=0.020), and ISS stage (overall P<0.001) were retained; age group (P=0.066) and incomplete treatment (HR 1.405, 95% CI 0.854-2.313; P=0.181) were not significant. LDH at least 250 U/L (HR 3.820, 95% CI 1.806-8.079; P<0.001) and beta-2 microglobulin at least 5.5 mg/L (HR 2.557, 95% CI 1.195-5.473; P=0.016) were associated with PFS. High-risk cytogenetics was not significant for OS (P=0.157) or PFS (P=0.057); separate R-ISS models were not significant overall. The three-factor score was evaluated in 101 derivation patients with 51 events (C-index 0.726; log-rank P<0.001) and 23 external patients with five events (C-index 0.844; P=0.037). Median OS was 84, 90, and 29 months in the derivation 0-, 1-, and 2-3-point groups, respectively, and was not reached, 58, and 38 months in the corresponding external groups. In pooled complete-case analysis (n=124), score groups differed for OS (P<0.001) and PFS (P=0.002).
Conclusions: In patients with MM aged 80 years or older, survival was governed less by chronologic age than by disease burden, functional reserve, and the ability to sustain therapy. A simple ISS-ECOG-treatment-course score identified a high-risk group across independent cohorts and may support early geriatric assessment, toxicity mitigation, and response-adapted treatment planning. Prospective validation with time-dependent modeling is warranted before clinical implementation.
DISCLOSURES
Jinuo Wang, MD: No relevant conflicts of interest to declare.